Trade Summary

4 days ago, Lerner Lorena Raquel, serving as Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 3,568 shares at $10.29 per share, for a total transaction value of $36,714.72. Following this transaction, Lerner Lorena Raquel now holds 27,559 shares of KROS.

This sale represents a 11.46% decrease in Lerner Lorena Raquel's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, August 18, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, August 20, 2026 at 4:10 PM ET, 2 days after the trade was made.

Keros Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.